| Followers | 59 |
| Posts | 7595 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Sunday, January 24, 2021 10:08:19 AM
Irishpaddy, In my life I hate to see anything go to waste. Be it human
potential or loaf of bread. Many of us on this board understood the
wonderful potential that Vascepa has with many indications beyond CVD.
For a myriad of reasons this particular medication is not receiving the
kind of reception that a safe and effective drug for the number one
killer should have. To put it very bluntly it is war of ignorance and
stupidity against logic and science. The last thing in the world I
want to see is an amazingly beneficial medication be "laid to waste."
For whatever reason(s) the management of AMRN has failed to get the
message of Vascepa to be accepted. I would like to see that changed.
People believe in Tesla because they believe it will change our world
for the better...I'm familiar with what Teslas can do...Amazing technologies at work there! Amarin, and Vascepa should be the Tesla
of the drug world. Pathetically, it is not. John Thero used to say
that 10's of millions would benefit from Vascepa. I still believe that.
My belief is that Vascepa will keep people healthier for a much longer
period of time if used properly. (My guess there is to start using it
before normal aging issues begin to crop up.) Vascepa is more than
just a CV drug or a drug to lower Triglyceride levels. Vascepa is
totally useless if it is not used! I DON'T WANT THIS TO GO TO WASTE!
potential or loaf of bread. Many of us on this board understood the
wonderful potential that Vascepa has with many indications beyond CVD.
For a myriad of reasons this particular medication is not receiving the
kind of reception that a safe and effective drug for the number one
killer should have. To put it very bluntly it is war of ignorance and
stupidity against logic and science. The last thing in the world I
want to see is an amazingly beneficial medication be "laid to waste."
For whatever reason(s) the management of AMRN has failed to get the
message of Vascepa to be accepted. I would like to see that changed.
People believe in Tesla because they believe it will change our world
for the better...I'm familiar with what Teslas can do...Amazing technologies at work there! Amarin, and Vascepa should be the Tesla
of the drug world. Pathetically, it is not. John Thero used to say
that 10's of millions would benefit from Vascepa. I still believe that.
My belief is that Vascepa will keep people healthier for a much longer
period of time if used properly. (My guess there is to start using it
before normal aging issues begin to crop up.) Vascepa is more than
just a CV drug or a drug to lower Triglyceride levels. Vascepa is
totally useless if it is not used! I DON'T WANT THIS TO GO TO WASTE!
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
